The incretin system ABCs in obesity and diabetes – novel therapeutic strategies for weight loss and beyond
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Summary: Incretins are gastrointestinal‐derived hormones released in response to a meal playing a key role in the regulation of postprandial secretion of insulin (incretin effect) and glucagon by the pancreas. Both incretins, glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1), have several other actions by peripheral and central mechanisms. GLP‐1 regulates body weight by inhibiting appetite and delaying gastric, emptying actions that are dependent on central nervous system GLP‐1 receptor activation. Several other hormones and gut peptides, including leptin and ghrelin, interact with GLP‐1 to modulate appetite. GLP‐1 is rapidly degraded by the multifunctional enzyme dipeptidyl peptidase‐4 (DPP‐4). DPP‐4 is involved in adipose tissue inflammation, which is associated with insulin resistance and diabetes progression, being a common pathophysiological mechanism in obesity‐related complications. Furthermore, the incretin system appears to provide the basis for understanding the high weight loss efficacy of bariatric surgery, a widely used treatment for obesity, often in association with diabetes. The present review brings together new insights into obesity pathogenesis, integrating GLP‐1 and DPP‐4 in the complex interplay between obesity and inflammation, namely, in diabetic patients. This in turn will provide the basis for novel incretin‐based therapeutic strategies for obesity and diabetes with promising benefits in addition to weight loss. © 2016 World Obesity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889 · cited 10×
“The latter derives from decreased proximal tubular sodium uptake because of reduced sodium–hydrogen exchanger 3 activity, curiously the same transporter that is stimulated by RAAS (22).”
BackgroundInfluentialRetractedESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction
Clément, K., Vaisse, C., Lahlou, N., Cabrol, S., Pelloux, V., Cassuto, D., Gourmelen, M., Dina, C., Chambaz, J., Lacorte, J.-M., et al. (1998) · Nature · doi:10.1038/32911 · Cited by 2,346
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164
The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review
Klok, M. D., Jakobsdottir, S., & Drent, M. L. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00270.x · Cited by 1,442 · cited 3×
“Whereas postprandially decreased, fasting plasmatic levels of ghrelin are high, thereby indicating its fast-acting role in meal initiation in humans (76).”
BackgroundMingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Nanni, G., Castagneto, M., Bornstein, S., & Rubino, F. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00075-6 · Cited by 1,220
Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C., Coupaye, M., Pelloux, V., Hugol, D., Bouillot, J.-L., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2277 · Cited by 1,164 · cited 1×
“Subsequent local necrosis and cytokines production, namely, chemotactic cytokines such as monocyte chemoattractant protein 1, stimulate macrophage infiltration (93).”
Backgroundon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Inflammasome is a central player in the induction of obesity and insulin resistance
Stienstra, R., van Diepen, J. A., Tack, C. J., Zaki, M. H., van de Veerdonk, F. L., Perera, D., Neale, G. A., Hooiveld, G. J., Hijmans, A., Vroegrijk, I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100255108 · Cited by 727
Kintscher, U., Hartge, M., Hess, K., Foryst-Ludwig, A., Clemenz, M., Wabitsch, M., Fischer-Posovszky, P., Barth, T. F. E., Dragun, D., Skurk, T., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.165100 · Cited by 692
From Blood Monocytes to Adipose Tissue-Resident Macrophages
Curat, C. A., Miranville, A., Sengenès, C., Diehl, M., Tonus, C., Busse, R., & Bouloumié, A. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1285 · Cited by 600 · cited 1×
“Moreover, leptin also seems to enhance blood monocyte diapedesis through effects on endothelial cells (94).”
Backgroundvan Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“In fact, chronic treatment with the GLP-1RA liraglutide in humans induced only minimal changes in energy expenditure (67).”
BackgroundInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Göke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 1×
“17, 553–572, July 2016 accessible to circulating GLP-1 through fenestrated capillaries (71), which can then activate GLP-1R present on neuronal cells in circumventricular organs (72).”
BackgroundEnergy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468 · cited 1×
“Although the ongoing dietary status was reported to alter the GLP-1R expression in the brain (58,59), these effects are nevertheless preserved in obese and T2DM subjects (25,60).”
BackgroundMuscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 3×
“impaired incretin effect are present in obese subjects with normal glucose tolerance, becoming more evident as glycemic control further deteriorates (11).”
BackgroundEffects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314 · cited 2×
“In fact, obesity is one of the main players on the genesis of T2DM, as supported by the fact that the majority of T2DM subjects are overweight (14).”
BackgroundThe bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain
Keitel, V., Görg, B., Bidmon, H. J., Zemtsova, I., Spomer, L., Zilles, K., & Häussinger, D. (2010) · Glia · doi:10.1002/glia.21049 · Cited by 274
Kohli, R., Bradley, D., Setchell, K. D., Eagon, J. C., Abumrad, N., & Klein, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3736 · Cited by 265
Gerich, J. E. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s117 · Cited by 264
Insulin resistance and cancer: The role of insulin and IGFs
Djiogue, S., Nwabo Kamdje, A. H., Vecchio, L., Kipanyula, M. J., Farahna, M., Aldebasi, Y., & Seke Etet, P. F. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0324 · Cited by 263
Delgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235 · cited 1×
“Using single-photon emission computed tomography, the authors found an increase in volume of the proximal and distal stomach in response to GLP-1 in both the fasting and fed states (74).”
MethodHyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
Mannucci, E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A., & Rotella, C. M. (2005) · Diabetologia · doi:10.1007/s00125-005-1749-8 · Cited by 206 · cited 2×
“17, 553–572, July 2016 diabetic animals and patients (45,46).”
BackgroundCeriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204
The central GLP-1: implications for food and drug reward
Skibicka, K. P. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00181 · Cited by 188
Monte, S. V., Caruana, J. A., Ghanim, H., Sia, C. L., Korzeniewski, K., Schentag, J. J., & Dandona, P. (2012) · Surgery · doi:10.1016/j.surg.2011.09.038 · Cited by 143 · cited 1×
“revealed a reduction in oxidative stress, systemic inflammation and IR (134), effects that are also shared to some extent”
BackgroundEffects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
Marques, C., Mega, C., Gonçalves, A., Rodrigues-Santos, P., Teixeira-Lemos, E., Teixeira, F., Fontes-Ribeiro, C., Reis, F., & Fernandes, R. (2014) · Mediators of Inflammation · doi:10.1155/2014/538737 · Cited by 126 · cited 4×
“In fact, antiinflammatory properties of such medications had already been demonstrated in the context of T2DM vascular complications, namely, regarding the diminution of proinflammatory cytokines (46,52,54).”
BackgroundInfluentialSelf-citationRonveaux, C. C., Tomé, D., & Raybould, H. E. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206029 · Cited by 124 · cited 10×
“In this context, GLP-1 acts in a paracrine manner on vagal afferent neurons (VANs); however, other modulators participate in this process.”
BackgroundInfluentialMechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94 · cited 1×
“Despite DPP-4-mediated degradation, GLP-1 and GIP are cleaved to a minor extent by several neutral endopeptidases and additional aminopeptidases (31) or extracted in the liver, extremities and lungs (32).”
BackgroundDerosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03699.x · Cited by 70 · cited 1×
“In addition, these agents are believed to confer direct β-cell cytoprotection (48,49).”
BackgroundAn Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49 · cited 1×
“Incretinbased therapies indeed improve metabolic control with minimal adverse effects (50,144).”
BackgroundTherapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43 · cited 6×
“The weight loss, even though moderate, is comparable with the approved drugs presently used to treat obesity, which in the case of the peripheral lipase inhibitor orlistat (Xenical®) cause inconvenient side effects, such as oily stools and faecal urgency (12,66,73,75).”
BackgroundInfluential
Cited by
Cardiovascular risk and obesity
Cercato, C., & Fonseca, F. A. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0468-0 · Cited by 395
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Zhao, C., Yang, C., Wai, S. T. C., Zhang, Y., P. Portillo, M., Paoli, P., Wu, Y., San Cheang, W., Liu, B., Carpéné, C., et al. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1501658 · Cited by 199
Insulin resistance: a connecting link between Alzheimer's disease and metabolic disorder
Kshirsagar, V., Thingore, C., & Juvekar, A. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-020-00622-2 · Cited by 66
“2012) and metabolic dysfunction in CNS can increase the probability of developing obesity and insulin resistance (João et al. 2016; Meier and Nauck 2010; Thon et al. 2016).”
Background
Metadata
- Authors
- João, A. L., Reis, F., & Fernandes, R.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2016-04-29
- Volume
- 17
- Issue
- 7
- Pages
- 553-572
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W2343373238
- Cited by
- 44
- References
- 36
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.